General Archive
-
News releasesTribune Therapeutics raises EUR 37 million for next-generation anti-fibrotic therapies
Tribune Therapeutics AB, a biotechnology company dedicated to treating the root causes of fibrotic diseases, today announced it has raised…
-
News releasesHillstar Bio closes $67 million Series A financing round
Hillstar Bio, a leading biotechnology company focused on developing next-generation precision immunology therapies for autoimmune diseases, today announced the successful…
-
News releasesLifeArc invests in Maxion Therapeutics Series A
Maxion Therapeutics (“Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases,…
-
BlogsReflecting on our commitment to involve patients and the public in our work
As we join with other partners to celebrate the third anniversary of the Shared Commitment to Public Involvement, it is…
-
BlogsReflections from the LifeArc Translational Science Summit on MND and Rare Dementias
On 5 March 2025, we hosted a Translational Science Summit on MND and Rare Dementias. From leading researchers, to venture…
-
News releasesLifeArc and Cleveland Clinic join forces to develop new monoclonal antibody therapeutics for patients with high unmet medical needs
LifeArc and Cleveland Clinic, a nonprofit, multispecialty academic medical centre, have signed a new 10-year Master Services Agreement (MSA) for…
-
ArticlesClare Terlouw, Head of LifeArc Ventures, talks to In Vivo’s Ashley Yeo on the improving investment climate
“There is a lot of capital out there in biotech land that has been largely locked up. Companies are coming…
-
News releasesLifeArc Ventures invests in Fluid Biomed
Fluid Biomed Inc., a clinical stage medical device company developing lifesaving products for patients suffering from vascular disease, closed an…
-
Blogs, Patient storiesLearning to live with a bronchiectasis diagnosis – Gaynor’s story
Grandmother of 4, Gaynor Hardman, was diagnosed with bronchiectasis at 61. With limited knowledge and understanding of this condition, she…
-
News releasesDr Sam Barrell CBE joins LifeArc as new CEO
We are excited to welcome Dr Sam Barrell, CBE, as she officially joins the LifeArc team today as our new…
-
News releasesLifeArc funds innovative rare liver disease clinical trial
The first patient has been recruited for the FARGO clinical trial, funded by LifeArc and PSC Support, which explores a…
-
ArticlesBronchiectasis: an overlooked lung condition with untapped commercial and research potential
Bronchiectasis (BE) is a chronic lung condition that significantly impacts the lives of many people in the UK and around…